EE39 Costs of Treating Hereditary Angioedema (HAE) Attacks with C1 Inhibitors in Four European Countries

Abstract

Hereditary angioedema (HAE) is a rare genetic disease caused by the deficiency or dysfunction of C1 esterase inhibitor (C1-INH), and characterized by recurring episodes of severe swelling, commonly affecting the skin, gastrointestinal tract, or upper airway (which can be life-threatening). Frequency and severity of attacks vary. Replacement C1-INH therapies provide effective relief; however, there is a lack of comparative data on economic outcomes.